阿布昔替尼联合外用治疗青少年中重度特应性皮炎:JADE TEEN随机临床试验
JADE TEEN是一项3期随机双盲安慰剂对照试验,纳入285例12-17岁中重度特应性皮炎青少年,比较口服阿布昔替尼200mg或100mg联合外用治疗与安慰剂联合外用治疗12周的疗效与安全性。结果显示阿布昔替尼组IGA 0/1、EASI-75和PP-NRS4应答率均显著高于安慰剂组,安全性可接受。
要点
- 阿布昔替尼200mg和100mg联合外用治疗12周IGA 0/1应答率分别为46.2%和41.6%,均高于安慰剂24.5%。
- EASI-75应答率阿布昔替尼200mg为72.0%、100mg为68.5%,安慰剂为41.5%。
- 恶心在阿布昔替尼200mg组更常见(18.1%),疱疹相关不良事件少见。
核心结论
- 口服阿布昔替尼联合外用治疗青少年中重度特应性皮炎较安慰剂联合外用治疗显著更有效,且安全性可接受。
研究设计与样本
- 3期随机双盲安慰剂对照试验JADE TEEN,在亚太、欧洲和北美开展,纳入285例12-17岁中重度特应性皮炎患者,按1:1:1随机接受阿布昔替尼200mg、100mg或安慰剂每日一次口服联合外用治疗12周。
主要发现
- 第12周IGA 0/1应答率:阿布昔替尼200mg组46.2%、100mg组41.6%,均高于安慰剂组24.5%(P<.05)。
- 第12周EASI-75应答率:阿布昔替尼200mg组72.0%、100mg组68.5%,均高于安慰剂组41.5%(P<.05)。
- 第12周PP-NRS4应答率:阿布昔替尼200mg组55.4%、100mg组52.6%,安慰剂组29.8%(200mg vs 安慰剂P<.01)。
- 不良事件发生率:阿布昔替尼200mg组62.8%、100mg组56.8%、安慰剂组52.1%;恶心在200mg组(18.1%)和100mg组(7.4%)更常见。
- 严重不良事件:阿布昔替尼200mg组1例(1.1%)、100mg组0例、安慰剂组2例(2.1%);疱疹相关不良事件少见。
关键数值与推荐
- 共同主要终点为第12周IGA应答(0或1分且较基线改善≥2级)和EASI-75应答。
- 关键次要终点包括第12周PP-NRS4应答(峰值瘙痒数字评定量表较基线改善≥4分)。
临床怎么用
- 对于12-17岁中重度特应性皮炎患者,若外用治疗应答不足或需要系统治疗,可考虑口服阿布昔替尼联合外用治疗。
- 使用阿布昔替尼时需监测恶心等不良事件,疱疹相关不良事件虽少见但仍需关注。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Dupilumab subcutaneous injection is approved for treating moderate-to-severe atopic dermatitis (AD) in adolescents, but there has been too little research on an efficacious systemic oral treatment with a favorable benefit-risk profile for adolescents with moderate-to-severe AD. OBJECTIVE: To investigate the efficacy and safety of oral abrocitinib plus topical therapy in adolescents with moderate-to-severe AD. DESIGN, SETTING, AND PARTICIPANTS: The phase 3, randomized, double-blind, placebo-controlled study JADE TEEN was conducted in countries of the Asia-Pacific region, Europe, and North America in patients aged 12 to 17 years with moderate-to-severe AD and an inadequate response to 4 consecutive weeks or longer of topical medication or a need for systemic therapy for AD. The study was conducted between February 18, 2019, and April 8, 2020. The data were analyzed after study completion. INTERVENTIONS: Patients were randomly assigned 1:1:1 to receive once-daily oral abrocitinib, 200 mg or 100 mg, or placebo for 12 weeks in combination with topical therapy. MAIN OUTCOMES AND MEASURES: Coprimary end points were achievement of an Investigator's Global Assessment (IGA) response of clear (0) or almost clear (1) with improvement of 2 or more grades from baseline (IGA 0/1) and 75% or greater improvement from baseline in Eczema Area and Severity Index (EASI-75) response at week 12. Key secondary end points included 4-point or greater improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) at week 12. Adverse events (AEs) were monitored. RESULTS: This study included 285 adolescents with moderate-to-severe AD (145 boys [50.9%] and 140 girls [49.1%]), of whom 160 (56.1%) were White and 94 (33.0%) were Asian; the median age was 15 years (interquartile range 13-17 years). Substantially more patients treated with abrocitinib (200 mg or 100 mg) vs placebo achieved an IGA response of 0/1 (46.2%; 41.6% vs 24.5%; P < .05 for both), EASI-75 (72.0%; 68.5% vs 41.5%; P < .05 for both), and PP-NRS4 (55.4%; 52.6% vs 29.8%; P < .01 for 200 mg vs placebo) at week 12. Adverse events were reported for 59 (62.8%), 54 (56.8%), and 50 (52.1%) patients in the 200 mg, 100 mg, and placebo groups, respectively; nausea was more common with abrocitinib, 200 mg (17 [18.1%]) and 100 mg (7 [7.4%]). Herpes-related AEs were infrequent; 1 (1.1%), 0, and 2 (2.1%) patients had serious AEs. CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that oral abrocitinib combined with topical therapy was significantly more effective than placebo with topical therapy in adolescents with moderate-to-severe AD, with an acceptable safety profile. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03796676.
引用
- Eichenfield LF, Flohr C, Sidbury R, et al. Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial. JAMA Dermatol. 2021. PMID: 34406366. doi:10.1001/jamadermatol.2021.2830
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。